Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Clinical Trial
Official title:
Brentuximab Vedotin (ADCETRIS) IV Infusion − Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting, as well as to collect efficacy information for reference.
The present survey was designed to evaluate the safety of brentuximab vedotin (recombinant)
for IV infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+
Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting.
The usual adult dosage is 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant)
infused intravenously once every three weeks. The dose should be adjusted depending on the
participant's condition. See the "PRECAUTIONS" section of the package insert.
;